Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. (November 2016)

• Record Type: Journal Article
• Authors: Ou, Dan; Blanchard, Pierre; El Khoury, Clément; De Felice, Francesca; Even, Caroline; Levy, Antonin; Nguyen, France; Janot, François; Gorphe, Philippe; Deutsch, Eric; Temam, Stephane; Tao, Yungan
• Is Part Of: Oral oncology. Volume 62(2016:Nov.)
• Page Start: 114
• Page End: 121
• Publication Date: 2016-11
• Subjects: Nasopharyngeal carcinoma -- Induction chemotherapy -- Concurrent chemoradiotherapy; Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2016.10.011
• Languages: English
• ISSNs: 1368-8375

Abstract

Highlights: No survival difference between 3 cycles TPF-IC followed by CCRT vs. CCRT alone. Less grade 3–4 late radiation morbidities were observed in the IC + CCRT group. Responsiveness of IC may provide prognostic information. Abstract: Objectives: To evaluate the efficacy of induction chemotherapy with docetaxel, cisplatin and fluorouracil (TPF) followed by concurrent chemoradiotherapy (IC + CCRT) or CCRT alone in non-endemic locally advanced nasopharyngeal carcinoma (NPC) patients. Materials and methods: Data of 106 patients with NPC treated from January 1999 to June 2012 with IC + CCRT (n = 58) or CCRT alone (n = 48) were retrospectively reviewed. Results: Median follow-up was 6.4 years. Distribution of age, performance status, stage and concurrent chemotherapy regimen were imbalanced between the two groups. The 5-year overall survival (OS) and progression-free survival (PFS) were not significantly different between IC + CCRT and CCRT groups (OS: 78.3% vs. 82.7%, p = 0.77; PFS: 72.5% vs. 68.2%, p = 0.81, respectively). There were less total cumulative incidence of grade 3–4 late radiation morbidity in the IC + CCRT group (44.8% vs. 70.8%, p = 0.01). Five-year OS for patients with post-IC complete response (CR), partial response (PR) and stable disease (SD) sub-groups were 100%, 79.4% and 60%, respectively. Conclusion: Compared with CCRT alone, IC (TPF regimen) + CCRT did not improve OS or PFS in patients with NPC, but less grade 3–4 late toxicities were observed. Responsiveness of IC may provide additional prognostic information.